Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,469 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hematopoietic stem cell transplant (HSCT) Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

NCT02572167
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
brentuximab vedotin, nivolumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Duarte, California • Stanford, California • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 9, 2026, 5:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT03064867
View directory record Official record
Conditions
Diffuse Large B-cell-lymphoma
Interventions
Venetoclax, Rituximab, Ifosfamide, Carboplatin, Etoposide
Drug
Lead sponsor
Molly Gallogly
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
St Louis, Missouri • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 9, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

NCT00225212
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma, Transformed Lymphoma, Other Subtypes of B-cell Lymphoma, Lymphoma
Interventions
Rituximab 375 mg/m2
Drug
Lead sponsor
Stanford University
Other
Eligibility
16 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 9, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

NCT01007292
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
YM155, Rituximab
Drug · Biological
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Columbus, Georgia • Maywood, Illinois • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 9, 2026, 5:41 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

NCT03394365
View directory record Official record
Conditions
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Interventions
tabelecleucel
Biological
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
Not listed
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
40
States / cities
Duarte, California • La Jolla, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 9, 2026, 5:41 PM EDT
Recruiting No phase listed Observational

Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

NCT02677064
View directory record Official record
Conditions
Acute Leukemia, Newly Diagnosed, Relapsed
Interventions
assessments
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
1,365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Hartford, Connecticut • New York, New York • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 9, 2026, 5:41 PM EDT
Not listed Phase 1 Interventional

Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

NCT00002616
View directory record Official record
Conditions
Breast Cancer
Interventions
aldesleukin, filgrastim, carboplatin, cyclophosphamide, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
Up to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 9, 2026, 5:41 PM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT02250937
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cladribine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Venetoclax
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 70 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Tandem Auto-Allo Transplant for Lymphoma

NCT01181271
View directory record Official record
Conditions
Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Interventions
Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant), Mesna (prior to AUTO transplant), autologous (auto) peripheral blood stem cell transplantation, Neupogen, Fludarabine (conditioning for ALLO Transplant), Busulfan (conditioning for ALLO Transplant), non-myeloablative allogeneic (allo) transplant, Tacrolimus, Sirolimus, Methotrexate
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 9, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Results available

Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients

NCT01215734
View directory record Official record
Conditions
Adult Stem Cell Hematopoetic Transplant
Interventions
High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV), Standard Dose Trivalent Inactivated Flu Vaccine
Biological
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 9, 2026, 5:41 PM EDT
Recruiting Phase 2 Interventional

Horizon Two: HR NDMM (MMRC-100)

NCT07053436
View directory record Official record
Conditions
High Risk Newly Diagnosed Multiple Myeloma
Interventions
Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 9, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma

NCT00574509
View directory record Official record
Conditions
Lymphoma
Interventions
131Iodine-Anti-B1 Radioimmunotherapy, BEAM
Radiation · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 9, 2026, 5:41 PM EDT
Completed No phase listed Observational

Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant

NCT00900406
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
gene expression analysis, microarray analysis, polymorphism analysis, proteomic profiling, flow cytometry, immunologic technique, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 9, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Haplo Peripheral Blood Sct In GVHD Prevention

NCT04473911
View directory record Official record
Conditions
GVHD, AML, ALL, MDS, MPN, CMML, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Blood Stem Cell Transplant Failure, Graft Vs Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Myelomonocytic Leukemia, Chemosensitive Hodgkin Lymphoma
Interventions
FLUDARABINE, CYCLOPHOSPHAMIDE, TBI, Melphalan, Sirolimus, Mycophenolate mofetil, RGI-2001
Drug · Radiation
Lead sponsor
Zachariah Michael DeFilipp
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 9, 2026, 5:41 PM EDT
Completed Not applicable Interventional Results available

A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors

NCT02492100
View directory record Official record
Conditions
Sexual Dysfunction
Interventions
Multi-modality sexual dysfunction intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 9, 2026, 5:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Computed Tomography and Biomarker Analysis in Diagnosing Coronary Artery Disease in Asymptomatic Patients Who Have Undergone Stem Cell Transplant

NCT02077218
View directory record Official record
Conditions
Cancer Survivor, Diabetes Mellitus, Hypertension
Interventions
computed tomography, cytology specimen collection procedure, laboratory biomarker analysis, questionnaire administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
45 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Oct 9, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

NCT01254578
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Adult Acute Promyelocytic Leukemia With PML-RARA, Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Alkylating Agent-Related Acute Myeloid Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Post-Transplant Lymphoproliferative Disorder, Primary Cutaneous B-Cell Non-Hodgkin Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Richter Syndrome, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, T-Cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 9, 2026, 5:41 PM EDT
Available No phase listed Expanded access

Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders

NCT03626285
View directory record Official record
Conditions
Benign Neoplasm, Bone Marrow Transplantation Recipient, Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm
Interventions
Bone Marrow Transplantation, CliniMACS CD34 Reagent System, Peripheral Blood Stem Cell Transplantation
Procedure · Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 9, 2026, 5:41 PM EDT
Terminated Not applicable Interventional Results available

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

NCT01598025
View directory record Official record
Conditions
Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Non-Hodgkins Lymphoma
Interventions
total-body irradiation (TBI), thiotepa, fludarabine phosphate, melphalan, anti-thymocyte globulin, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis
Radiation · Drug · Biological + 2 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 19 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 9, 2026, 5:41 PM EDT
Completed Not applicable Interventional

Peer Support Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT06010017
View directory record Official record
Conditions
Hematopoietic Neoplasms, Hematopoietic Malignancy
Interventions
STEPP Intervention
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 9, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT00729118
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
lenalidomide, vorinostat
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 9, 2026, 5:41 PM EDT
Completed No phase listed Observational

Iron Overload in Stem Cell Transplant Recipients

NCT00806715
View directory record Official record
Conditions
Iron Overload
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Oct 9, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02085408
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Daunorubicin, Cytarabine, Clofarabine, Decitabine, Observation, Allogeneic hematopoietic stem cell transplantation
Drug · Other · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
60 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
266
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 181 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 9, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)

NCT00350818
View directory record Official record
Conditions
Myelodysplastic Syndrome, Leukemia
Interventions
Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 9, 2026, 5:41 PM EDT